| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenues, net | $797K+10301.1% | $8K-91.4% | $89K-58.3% | $214K+343.0% | $48K-60.6% | $123K |
| Cost of implants and other costs | $22K+1207.9% | $2K-95.4% | $36K+135.5% | $15K+159.8% | $6K-93.9% | $96K |
| Research and development | $1.8M+19.3% | $1.5M+66.4% | $891K-38.9% | $1.5M-9.1% | $1.6M-62.4% | $4.3M |
| Selling, general and administrative | $3.8M+5.0% | $3.6M+25.6% | $2.9M-15.7% | $3.4M-8.9% | $3.7M+18.1% | $3.2M |
| Depreciation and amortization | $44K+32.8% | $33K+23.6% | $27K-2.3% | $27K-57.3% | $64K-16.7% | $77K |
| Total operating expenses | $5.6M+9.7% | $5.1M+32.3% | $3.9M-21.1% | $4.9M-11.6% | $5.6M-27.0% | $7.6M |
| Loss from operations | -$4.8M+5.7% | -$5.1M-35.2% | -$3.8M+19.4% | -$4.7M+14.7% | -$5.5M+26.5% | -$7.5M |
| Interest expense - related parties | -$638K+15.1% | -$751K-8.4% | -$693K+26.0% | -$936K-71.3% | -$546K | — |
| Interest expense, net | -$224K+71.2% | -$777K-300.3% | -$194K-28.5% | -$151K-677.2% | -$19K+96.2% | -$511K |
| Loss on settlement of debt | -$188K-13.9% | -$165K-379.4% | -$34K+82.7% | -$199K | $0 | — |
| Grant income | $2.4M+65.3% | $1.5M+57.9% | $933K-47.9% | $1.8M+114.1% | $836K-81.3% | $4.5M |
| Change in fair value of upfront purchase price liability | -$7K | $0 | — | — | — | — |
| Change in fair value of royalty liability | -$280K | $0 | — | — | — | — |
| Other miscellaneous income | $223K+72.5% | $129K+2350.8% | $5K-96.2% | $139K+376.9% | $29K-8.1% | $32K |
| Total other (expenses) income, net | $1.3M+1576.5% | -$90K-617.7% | $17K-94.6% | $321K | — | $4.0M |
| Loss before provision for income taxes | -$3.5M+32.7% | -$5.2M-38.2% | -$3.8M+13.9% | -$4.4M+16.0% | -$5.2M | — |
| Income taxes | $0 | $0 | $0 | $0 | $0 | $0 |
| Net loss | -$3.5M+32.7% | -$5.2M-38.2% | -$3.8M+13.9% | -$4.4M+16.0% | -$5.2M-48.6% | -$3.5M |
| Non-controlling interest | $69K-35.3% | $106K+2862.8% | $4K-51.8% | $7K+211.2% | $2K-93.0% | $34K |
| Net loss attributable to BioCorRx Inc. | -$3.4M+32.6% | -$5.1M-35.6% | -$3.8M+13.8% | -$4.4M+17.2% | -$5.3M-52.0% | -$3.5M |
| Net loss per common share, basic and diluted | -$0.19+61.2% | -$0.49-8.9% | -$0.45+26.2% | -$0.61+24.7% | -$0.81-24.6% | -$0.65 |
| Weighted average number of common shares outstanding, basic and diluted | 18.5M+76.7% | 10.5M+25.4% | 8.3M+15.9% | 7.2M+10.9% | 6.5M+20.7% | 5.4M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.